71845-20-0

Usage

Uses

Used in Pharmaceutical Synthesis:
[4-(2-Phenylethyl)phenyl]aminehydrochloride is used as a building block in the synthesis of drugs and other bioactive compounds for its potential to interact with biological systems. The amine group allows for versatile chemical modifications, facilitating the creation of new pharmaceutical agents.
Used in Organic Chemistry:
In the field of organic chemistry, [4-(2-Phenylethyl)phenyl]aminehydrochloride is utilized as an intermediate in the synthesis of complex organic molecules, leveraging its phenyl and 2-phenylethyl groups for structural and functional diversification.
Used in Medicinal Chemistry:
[4-(2-Phenylethyl)phenyl]aminehydrochloride is employed as a component in medicinal chemistry for its ability to be integrated into drug molecules, potentially enhancing their pharmacological properties, such as affinity for biological targets and overall efficacy.
Used in Chemical and Biological Research:
[4-(2-PHENYLETHYL)PHENYL]AMINEHYDROCHLORIDE serves as a research tool in both chemical and biological studies, where its unique structure can be explored for understanding interactions with various biomolecules and for developing new methodologies in synthetic chemistry.

Upstream product

• 1694-20-8 trans-4-nitrostilbene 
• 1694-20-8 4-nitrostilbene 

Downstream Products

• 1263998-59-9 5-(2-phenylethyl)isatin 
• 91459-41-5 5-(2-phenylethyl)-1H-indole 

Relevant academic research and scientific papers

Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues

Previous studies have shown that (E)-5-styrylisatin and (E)-6-styrylisatin are reversible inhibitors of human monoamine oxidase (MAO) A and B. Both homologues are reported to exhibit selective binding to the MAO-B isoform with (E)-5-styrylisatin being the most potent inhibitor. To further investigate these structure-activity relationships (SAR), in the present study, additional C5- and C6-substituted isatin analogues were synthesized and evaluated as inhibitors of recombinant human MAO-A and MAO-B. With the exception of 5-phenylisatin, all of the analogues examined were selective MAO-B inhibitors. The C5-substituted isatins exhibited higher binding affinities to MAO-B than the corresponding C6-substituted homologues. The most potent MAO-B inhibitor, 5-(4-phenylbutyl) isatin, exhibited an IC50 value of 0.66 nM, approximately 13-fold more potent than (E)-5-styrylisatin and 18,500-fold more potent than isatin. The most potent MAO-A inhibitor was found to be 5-phenylisatin with an IC 50 value of 562 nM. The results document that substitution at C5 with a variety of substituents is a general strategy for enhancing the MAO-B inhibition potency of isatin. Possible binding orientations of selected isatin analogues within the active site cavities of MAO-A and MAO-B are proposed.

5-HT-1D receptor ligands

Described herein are tryptamine analogs that display high binding affinity and selectivity for the 5-HT1Dβ receptor, of the formula: STR1 wherein R 1 is a group selected from aryl-C 1-7 alkyl; aryl-C 2-7 alkoxy; aryl-C 2-7 alkanoyl and aryl-C 1-7 alkanoyloxy, wherein said alkyl, alkoxy, alkanoyl and alkanoyloxy groups are optionally substituted by a C 1-4 alkyl substituent and wherein said aryl group is optionally substituted by one or more substituent selected from hydroxyl, halogen, mercapto, linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy, linear or branched C 1-4 alkylthio, thiol substituted C 1-4 alkyl and nitro substituted C 1-4 alkyl;R 2 and R 3 are selected independently from H and C 1-4 alkyl; andR 4 is selected from H, C 1-4 alkyl, aryl and arylC 1-4 alkyl. The compounds are useful as reagents for receptor identification and in receptor-based drug screening programs, and can also be used therapeutically to treat conditions for which administration of a 5-HT1D ligand is indicated, for example in the treatment of migraine.